Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 73Sarcoma 9Thoracic 3Gynecologic 3Genitourinary 3Head & Neck 2CNS 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Brain Neoplasms 2

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × eribulin × CNS × Clear all
NCT02581839 2020-07-30

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

Case Comprehensive Cancer Center

Phase 2 Completed
9 enrolled 14 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03637868 2020-05-06

ERIBRAIN

Institut Paoli-Calmettes

Phase 2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡